Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) CEO Sells $10,560,000.00 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) CEO Richard Francis sold 250,000 shares of the business’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the completion of the sale, the chief executive officer directly owned 927,529 shares of the company’s stock, valued at $39,178,824.96. This represents a 21.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded up $0.28 during trading on Thursday, hitting $43.52. The company had a trading volume of 9,218,408 shares, compared to its average volume of 6,859,138. The firm has a market capitalization of $50.72 billion, a P/E ratio of 101.22, a price-to-earnings-growth ratio of 3.97 and a beta of 0.97. Teva Pharmaceutical Industries Ltd. has a one year low of $24.01 and a one year high of $44.31. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The stock’s 50-day moving average price is $39.88 and its 200 day moving average price is $34.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.14. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. Teva Pharmaceutical Industries’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.78 earnings per share. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Top Teva Pharmaceutical Industries Stories

These are some of the TEVA stories that stood out recently:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and upgraded Teva to “overweight,” implying about 28% upside from the cited $43.74 share price. Piper Sandler ratings
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it raised its FY2027 EPS forecast to $3.07 from $3.03, but lowered estimates for some individual quarters, including Q4 2026 and Q3 2027. Its overall rating remains “Buy” with a $52 target. Teva analyst information
• Negative Sentiment: Healthcare shares were weaker in Wednesday afternoon trading, with the NYSE Healthcare Index down 0.6%, creating a possible sector-level headwind for TEVA. Healthcare sector update

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Cornerstone Planning Group LLC grew its position in Teva Pharmaceutical Industries by 547.1% during the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the last quarter. Root Financial Partners LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $33,000. Western Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $43,000. Sunbelt Securities Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $45,000. Finally, EverSource Wealth Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 64.0% in the first quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock worth $50,000 after purchasing an additional 647 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. TD Cowen raised their target price on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. HC Wainwright began coverage on Teva Pharmaceutical Industries in a research note on Monday, November 2nd. They issued a “buy” rating and a $52.00 price objective on the stock. Finally, Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.15.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.